RESUMEN
Human prominin-1 (CD133 or AC133) is an important cell surface marker used to isolate primitive hematopoietic stem cells. The commercially available antibody to human prominin-1 does not recognize rhesus prominin-1. Therefore, we isolated, cloned and characterized the complementary DNA (cDNA) of rhesus prominin-1 gene and determined its coding potential. Following the nomenclature of prominin family of genes, we named this cDNA as rhesus prominin-1.s1. The amino acid sequence data of the putative rhesus prominin-1.s1 could be used in designing antigenic peptides to raise antibodies for use in isolation of pure populations of rhesus prominin-1(+) hematopoietic cells. To the best of our knowledge, there has been no previously published report about the isolation of a prominin-1 cDNA from rhesus monkey (Macaca mulatta).
Asunto(s)
Antígenos CD/biosíntesis , Antígenos CD/aislamiento & purificación , Clonación Molecular , ADN Complementario/biosíntesis , ADN Complementario/aislamiento & purificación , Glicoproteínas/biosíntesis , Glicoproteínas/aislamiento & purificación , Células Madre Hematopoyéticas/inmunología , Péptidos/aislamiento & purificación , Antígeno AC133 , Secuencia de Aminoácidos , Animales , Antígenos CD/genética , Secuencia de Bases , Marcadores Genéticos , Glicoproteínas/genética , Células Madre Hematopoyéticas/metabolismo , Humanos , Macaca mulatta , Ratones , Datos de Secuencia Molecular , Péptidos/genética , RatasRESUMEN
Selective inhibition of the BCR/ABL tyrosine kinase by imatinib has become a first-line therapy for chronic myelogenous leukemia (CML). However, BCR/ABL-positive progenitors often persist despite treatment, and relapse associated with resistance to imatinib has been described in many patients with advanced disease. Drug efflux by P-glycoprotein (P-gp), as well as point mutations in BCR/ABL oncoprotein, has been implicated in the mechanism of resistance to imatinib. In this study, we established a murine transplantation model of CML-like myeloproliferative disease using Mdr1a/1b-null mice and analyzed the effects of loss of P-gp on resistance to imatinib. We found that mice transplanted with Mdr1a/1b-null bone marrow (BM) that had been transduced with a BCR/ABL retroviral vector displayed similar responses to imatinib, compared with those transplanted with BCR/ABL-transduced wild-type BM. In the absence of P-gp, the incidence and latency of disease in secondary recipients was not changed in imatinib-treated mice, relative to wild-type controls. Furthermore, K562 cells engineered to overexpress P-gp remained sensitive to imatinib-induced growth inhibition and cell death. Together, our findings suggest that P-gp expression in hematopoietic stem cells does not significantly contribute to imatinib resistance in CML.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/biosíntesis , Modelos Animales de Enfermedad , Células Madre Hematopoyéticas/metabolismo , Leucemia Mielógena Crónica BCR-ABL Positiva/tratamiento farmacológico , Leucemia Mielógena Crónica BCR-ABL Positiva/metabolismo , Piperazinas/farmacología , Pirimidinas/farmacología , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Animales , Benzamidas , Trasplante de Médula Ósea/métodos , Supervivencia Celular/efectos de los fármacos , Trasplante de Células , Resistencia a Antineoplásicos , Humanos , Mesilato de Imatinib , Células K562 , Ratones , Ratones Noqueados , Análisis de SupervivenciaRESUMEN
Stem cells from bone marrow, skeletal muscle and possibly other tissues can be identified by the 'side-population' (SP) phenotype. Although it has been assumed that expression of ABC transporters is responsible for this phenotype, the specific molecules involved have not been defined. Here we show that expression of the Bcrp1 (also known as Abcg2 murine/ABCG2 human) gene is a conserved feature of stem cells from a wide variety of sources. Bcrp1 mRNA was expressed at high levels in primitive murine hematopoietic stem cells, and was sharply downregulated with differentiation. Enforced expression of the ABCG2 cDNA directly conferred the SP phenotype to bone-marrow cells and caused a reduction in maturing progeny both in vitro and in transplantation-based assays. These results show that expression of the Bcrp1/ABCG2 gene is an important determinant of the SP phenotype, and that it might serve as a marker for stem cells from various sources.
Asunto(s)
Transportadoras de Casetes de Unión a ATP/metabolismo , Proteínas Inflamatorias de Macrófagos , Glicoproteínas de Membrana , Proteínas Asociadas a Resistencia a Múltiples Medicamentos , Proteínas de Neoplasias , Células Madre/fisiología , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2 , Transportadoras de Casetes de Unión a ATP/genética , Animales , Antígenos CD/metabolismo , Antígenos CD34/metabolismo , Biomarcadores , Células de la Médula Ósea/fisiología , Células Cultivadas , Quimiocinas CC , Citocinas/metabolismo , Femenino , Humanos , Masculino , Ratones , Ratones Endogámicos , Ratones Mutantes , Proteínas Ribosómicas/metabolismo , Células Madre/citología , Tetraspanina 29 , TrasplantesRESUMEN
Transduction of murine stem cells with a multidrug-resistance 1 gene (MDR1) retrovirus results in dramatic ex vivo and in vivo expansion of repopulating cells accompanied by a myeloproliferative disorder. Given the use of MDR1-containing vectors in human trials, investigations have been extended to nonhuman primates. Peripheral blood stem cells from 2 rhesus monkeys were collected, CD34-enriched, split into 2 portions, and transduced with either MDR1 vectors or neo vectors and continued in culture for a total of 10 days before reinfusion. At engraftment, the copy number in granulocytes was extremely high from both MDR vectors and neo vectors, but the copy number fell to 0.01 to 0.05 for both. There were no perturbations of the leukocyte count or differential noted. After 3 cycles of stem cell factor/granulocyte colony-stimulating factor, there were no changes in the levels of MDR1 vector- or neo vector-containing cells. There was no evidence for expansion of MDR1 vector-transduced cells. Long-term engraftment with MDR1 vector- and neo vector-transduced cells occurred despite prolonged culture.
Asunto(s)
Farmacorresistencia Microbiana/genética , Genes MDR/genética , Terapia Genética/métodos , Trasplante de Células Madre Hematopoyéticas/métodos , Animales , Técnicas de Cultivo de Célula , División Celular/efectos de los fármacos , Dosificación de Gen , Terapia Genética/normas , Vectores Genéticos/efectos adversos , Vectores Genéticos/normas , Trasplante de Células Madre Hematopoyéticas/normas , Células Madre Hematopoyéticas/efectos de los fármacos , Humanos , Macaca mulatta , Modelos Animales , Neomicina , Transducción Genética/métodos , Transducción Genética/normasRESUMEN
The fibronectin fragment CH-296 improved gene transfer to cytokine-mobilized nonhuman primate CD34+ cells irrespective of tropism to the MoMLV, GaLV, and VSV-G envelope proteins using murine stem cell virus (MSCV) and human immunodeficiency virus-1 (HIV-1)-based retrovirus vectors. For the HIV-1 lentivirus vector, CH-296 enhanced gene transfer in the absence of added hematopoietic growth factors necessary for ex vivo stem cell expansion. In the presence of CH-296, apoptosis of CD34+ cells was inhibited, and in mobilized peripheral blood CD34+ cells, cell division was stimulated as measured by cell history/tracking experiments.
Asunto(s)
Fibronectinas/genética , Gammaretrovirus/genética , Técnicas de Transferencia de Gen , Vectores Genéticos , VIH-1/genética , Células Madre Hematopoyéticas/metabolismo , Animales , Antígenos CD34 , Apoptosis , Línea Celular , Fibronectinas/metabolismo , Terapia Genética , Células Madre Hematopoyéticas/citología , Células Madre Hematopoyéticas/efectos de los fármacos , Humanos , Macaca mulatta , Virus de la Leucemia Murina de Moloney/genética , Fragmentos de Péptidos/genética , Fragmentos de Péptidos/metabolismo , Transducción Genética , Tropismo , Proteínas del Envoltorio Viral/genética , Replicación ViralRESUMEN
Transfer of drug resistance genes to hematopoietic stem cells offers the potential to protect cancer patients from drug-induced myelosuppression and to increase the number of gene-modified cells by in vivo selection. In this study, a retroviral vector expressing both a P140K variant of human O6-methylguanine-DNA methyltransferase (MGMT) and an EGFP reporter gene was evaluated for stem cell protection in a murine transplant model. Mice transplanted with vector-transduced cells showed significant resistance to the myelosuppressive effects of temozolomide (TMZ), an orally administered DNA-methylating drug, and O6-benzylguanine (BG), a drug that depletes cells of wild-type MGMT activity. Following drug treatment, increases in EGFP(+) peripheral blood cells were seen in all peripheral blood lineages, and secondary transplant experiments proved that selection had occurred at the stem cell level. In a second set of experiments in which transduced cells were diluted with unmarked cells, efficient stem cell selection was noted together with progressive marrow protection with repeated treatment courses. Altogether, these results show that P140K MGMT gene transfer can protect stem cells against the toxic effects of TMZ and BG and that this vector/drug system may be useful for clinical myeloprotection and for in vivo selection of transduced stem cells.
Asunto(s)
Transferasas Alquil y Aril/genética , Dacarbazina/análogos & derivados , Dacarbazina/farmacología , Vectores Genéticos , Guanina/análogos & derivados , Guanina/farmacología , Células Madre Hematopoyéticas/citología , Células Madre Hematopoyéticas/fisiología , Retroviridae/genética , Animales , Antineoplásicos Alquilantes/farmacología , Linfocitos B/metabolismo , Plaquetas/metabolismo , Southern Blotting , Técnicas de Cultivo de Célula/métodos , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/farmacología , Eritrocitos/metabolismo , Femenino , Citometría de Flujo , Granulocitos/metabolismo , Proteínas Fluorescentes Verdes , Trasplante de Células Madre Hematopoyéticas , Hemoglobinas/metabolismo , Proteínas Luminiscentes/genética , Ratones , Ratones Endogámicos C57BL , Modelos Genéticos , Neutrófilos/metabolismo , Plásmidos/metabolismo , Linfocitos T/metabolismo , Temozolomida , Factores de TiempoRESUMEN
Janus kinase 3 (JAK3) is an essential component of cytokine receptor signal transduction pathways required for normal lymphocyte development and function. JAK3 deficiency in both mice and humans results in severe combined immunodeficiency (SCID) and increased susceptibility to opportunistic infections. We have previously shown that JAK3 gene transfer into irradiated recipients could restore immune function. However, since this toxic conditioning would be undesirable for infants in a clinical application, we have tested whether immune function could be restored in nonmyeloablated JAK3-deficient (-/-) mice. Murine JAK3 retroviral vectors were transduced into hematopoietic stem cells from the livers of newborn JAK3(-/-) mice. These cells were then injected intraperitoneally into nonirradiated JAK3(-/-) neonates. Transduced cells were detectable in these mice at time points 4 to 6 months after injection and resulted in significant correction of T and B lymphocyte numbers and circulating immunoglobulin (Ig) levels. After immune challenge with a dose of influenza A virus that was lethal to nonmanipulated JAK3(-/-) mice, mice injected with transduced cells showed development of circulating virus-specific IgG and enhanced survival. This work shows that the large selective advantage for JAK3-corrected lymphoid cells may be sufficient to overcome the need for myeloablative conditioning in JAK3 gene therapy protocols.
Asunto(s)
Terapia Genética/métodos , Células Madre Hematopoyéticas/fisiología , Linfocitos/fisiología , Proteínas Tirosina Quinasas/deficiencia , Proteínas Tirosina Quinasas/genética , Inmunodeficiencia Combinada Grave/terapia , Animales , Animales Recién Nacidos , Formación de Anticuerpos , Trasplante de Células , Vectores Genéticos , Virus de la Influenza A/patogenicidad , Janus Quinasa 3 , Hígado/citología , Ratones , Ratones Mutantes , Células Mieloides/fisiología , Infecciones por Orthomyxoviridae/inmunología , Fenotipo , Retroviridae/genética , Selección Genética , Inmunodeficiencia Combinada Grave/inmunología , Inmunodeficiencia Combinada Grave/patología , Tasa de SupervivenciaRESUMEN
The human multidrug resistance-1 (MDR1) gene product, P-glycoprotein (P-gp), is well known for its ability to confer drug resistance; however, recent evidence suggests that P-gp expression can have more general effects on cellular development. In support of this idea, it was previously shown that retroviral-mediated MDR1 expression in murine bone marrow cells resulted in the expansion of stem cells in culture and in the development of a myeloproliferative syndrome in transplanted mice. It is now reported that MDR1-mediated stem cell expansion is associated with an increase in side population (SP) stem cells, defined by Hoechst dye staining. Transduction of murine bone marrow cells with an MDR1 retroviral vector resulted in an almost 2 log increase in SP cell numbers over 12 days in culture, whereas there was a rapid loss of SP cells from control cultures. Stem cell amplification was not limited to ex vivo expansion cultures but was also evident when MDR1-transduced cells were directly transplanted into irradiated mice. In these cases, stem cell expansion was associated with relatively high vector copy numbers in stem cell clones. As previously reported, some cases were associated with a characteristic myeloproliferative syndrome. A functionally inactive MDR1 mutant cDNA was used to show that P-gp pump function was required both for amplification of phenotypically defined SP cells and functionally defined repopulating cells. These studies further support the concept that ABC transporter function can have important effects on hematopoietic stem cell development.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Técnicas de Transferencia de Gen , Células Madre Hematopoyéticas/citología , Células Madre Hematopoyéticas/fisiología , Animales , Recuento de Células Sanguíneas , Diferenciación Celular/genética , División Celular/genética , Expresión Génica , Vectores Genéticos , Humanos , Ratones , RetroviridaeRESUMEN
Tumors resistant to chemotherapeutic oxazaphosphorines such as cyclophosphamide often overexpress aldehyde dehydrogenase (ALDH), some isozymes of which catalyze the oxidization of aldophosphamide, an intermediate of cyclophosphamide activation, with formation of inert carboxyphosphamide. Since resistance to oxazaphosphorines can be produced in mammalian cells by transfecting them with the gene for human ALDH isozyme 3 (hALDH3), it seems possible that patients receiving therapy for solid tumors with cyclophosphamide might be protected from myelosuppression by their prior transplantation with autologous bone marrow that has been transduced with a retroviral vector causing overexpression of hALDH3. We investigated whether retroviral introduction of hALDH3 into a human leukemia cell line confers resistance to oxazaphosphorines. This was examined in the polyclonal transduced population, that is, without selecting out high expression clones. hALDH3 activity was 0.016 IU/mg protein in the transduced cells (compared with 2x10(-5) IU/mg in untransduced cells), but there was no detectable resistance to aldophosphamide-generating compounds (mafosfamide or 4-hydroperoxycyclophosphamide). The lack of protection was due, in part, to low catalytic activity of hALDH3 towards aldophosphamide, since, with NAD as cofactor, the catalytic efficiency of homogeneous, recombinant hALDH3 for aldophosphamide oxidation was shown to be about seven times lower than that of recombinant hALDH1. The two polymorphic forms of hALDH3 had identical kinetics with either benzaldehyde or aldophosphamide as substrate. Results of initial velocity measurements were consistent with an ordered sequential mechanism for ALDH1 but not for hALDH3; a kinetic mechanism for the latter is proposed, and the corresponding rate equation is presented.
Asunto(s)
Aldehído Deshidrogenasa/metabolismo , Antineoplásicos/metabolismo , Mostazas de Fosforamida/metabolismo , Aldehído Deshidrogenasa/química , Aldehído Deshidrogenasa/genética , Familia de Aldehído Deshidrogenasa 1 , Aldehídos/metabolismo , Antineoplásicos/farmacología , Benzaldehídos/metabolismo , Clonación Molecular , Ciclofosfamida/análogos & derivados , Ciclofosfamida/farmacología , ADN Complementario/análisis , Inhibidores Enzimáticos/farmacología , Células Madre Hematopoyéticas/efectos de los fármacos , Humanos , Isoenzimas/química , Isoenzimas/genética , Isoenzimas/metabolismo , Cinética , Oxidación-Reducción , Mostazas de Fosforamida/farmacología , Proteínas Recombinantes/química , Retinal-Deshidrogenasa , Análisis de Secuencia , Especificidad por Sustrato , Transfección , Células Tumorales CultivadasRESUMEN
Antifolate drugs such as methotrexate are commonly used in cancer chemotherapy. It may be possible to increase the antitumor activity of antifolates by the coadministration of drugs that inhibit nucleoside transport, thereby blocking the capacity of tumor cells to salvage nucleotide precursors. An important limitation of this approach is severe myelosuppression caused by many of these drug combinations. For this reason, we have developed a gene therapy strategy to protect bone marrow cells against combined treatment with antifolates and nitrobenzylmercaptopurine riboside (NBMPR), a potent inhibitor of the es nucleoside transporter. A retroviral vector (MeiIRG) was constructed that expressed the NBMPR-insensitive ei transporter, hypothesizing that transduced bone marrow cells would survive drug treatment because of the preservation of nucleoside salvage pathways. In vitro clonogenic assays confirmed that the MeiIRG vector did protect myeloid progenitors against the toxic effects of 3 different antifolates when each was combined with NBMPR. On testing this system in vivo, decreased myelosuppression was observed in mice transplanted with MeiIRG-transduced bone marrow cells and subsequently treated with trimetrexate and NBMPR-P. In these mice, significant increases were noted in absolute neutrophil count nadirs, reticulocyte indices, and the numbers of myeloid progenitors in the bone marrow. Furthermore, a survival advantage was associated with transfer of the MeiIRG vector, indicating that significant dose intensification was possible with this approach. In summary, the MeiIRG vector can decrease the toxicity associated with the combined use of antifolates and NBMPR-P and thereby may provide a strategy for simultaneously sensitizing tumor cells while protecting hematopoietic cells.
Asunto(s)
Proteínas Portadoras/genética , ADN Complementario/genética , Resistencia a Medicamentos/genética , Transportador Equilibrativo 2 de Nucleósido , Antagonistas del Ácido Fólico/farmacología , Técnicas de Transferencia de Gen , Proteínas de la Membrana/genética , Retroviridae/genética , Células 3T3 , Animales , Células de la Médula Ósea/efectos de los fármacos , Proteínas Portadoras/antagonistas & inhibidores , Proteínas Portadoras/fisiología , Muerte Celular/efectos de los fármacos , Sinergismo Farmacológico , Femenino , Vectores Genéticos , Glutamatos/farmacología , Guanina/análogos & derivados , Guanina/farmacología , Células Madre Hematopoyéticas/efectos de los fármacos , Proteínas de la Membrana/antagonistas & inhibidores , Proteínas de la Membrana/fisiología , Ratones , Ratones Endogámicos C57BL , Pemetrexed , Quinazolinas/farmacología , Tioinosina/análogos & derivados , Tioinosina/farmacología , Tiofenos/farmacologíaRESUMEN
We have used a murine retrovirus vector containing an enhanced green fluorescent protein complimentary DNA (EGFP cDNA) to dynamically follow vector-expressing cells in the peripheral blood (PB) of transplanted rhesus macaques. Cytokine mobilized CD34(+) cells were transduced with an amphotropic vector that expressed EGFP and a dihydrofolate reductase cDNA under control of the murine stem cell virus promoter. The transduction protocol used the CH-296 recombinant human fibronectin fragment and relatively high concentrations of the flt-3 ligand and stem cell factor. Following transplantation of the transduced cells, up to 55% EGFP-expressing granulocytes were obtained in the peripheral circulation during the early posttransplant period. This level of myeloid marking, however, decreased to 0.1% or lower within 2 weeks. In contrast, EGFP expression in PB lymphocytes rose from 2%-5% shortly following transplantation to 10% or greater by week 5. After 10 weeks, the level of expression in PB lymphocytes continued to remain at 3%-5% as measured by both flow cytometry and Southern blot analysis, and EGFP expression was observed in CD4(+), CD8(+), CD20(+), and CD16/56(+) lymphocyte subsets. EGFP expression was only transiently detected in red blood cells and platelets soon after transplantation. Such sustained levels of lymphocyte marking may be therapeutic in a number of human gene therapy applications that require targeting of the lymphoid compartment. The transient appearance of EGFP(+) myeloid cells suggests that transduction of a lineage-restricted myeloid progenitor capable of short-term engraftment was obtained with this protocol. (Blood. 2000;95:445-452)
Asunto(s)
Citocinas/farmacología , Granulocitos/citología , Trasplante de Células Madre Hematopoyéticas , Células Madre Hematopoyéticas/citología , Proteínas Luminiscentes/genética , Tetrahidrofolato Deshidrogenasa/genética , Transfección/métodos , Animales , ADN Complementario/administración & dosificación , Fibronectinas/farmacología , Proteínas Fluorescentes Verdes , Movilización de Célula Madre Hematopoyética , Células Madre Hematopoyéticas/efectos de los fármacos , Células Madre Hematopoyéticas/fisiología , Humanos , Proteínas Luminiscentes/biosíntesis , Subgrupos Linfocitarios/inmunología , Linfocitos/citología , Linfocitos/inmunología , Macaca mulatta , Fragmentos de Péptidos/farmacología , Regiones Promotoras Genéticas , Proteínas Recombinantes de Fusión/biosíntesis , Proteínas Recombinantes/farmacología , Tetrahidrofolato Deshidrogenasa/biosíntesisAsunto(s)
Separación Celular/métodos , Vectores Genéticos , Células Madre Hematopoyéticas/citología , Retroviridae/genética , Tetrahidrofolato Deshidrogenasa/genética , Transducción Genética , Regulación Enzimológica de la Expresión Génica/fisiología , Regulación Viral de la Expresión Génica/fisiología , HumanosRESUMEN
Ex vivo expansion of hematopoietic stem cells would be useful for bone marrow transplantation and gene therapy applications. Toward this goal, we have investigated whether retrovirally-transduced murine stem cells could be expanded in culture with hematopoietic cytokines. Bone marrow cells were transduced with retroviral vectors expressing either the human multidrug resistance 1 gene (HaMDR1), a variant of human dihydrofolate reductase (HaDHFR), or both MDR1 and DHFR in an internal ribosomal entry site (IRES)-containing bicistronic vector (HaMID). Cells were then expanded for 15 days in cultures stimulated with interleukin (IL)-3, IL-6, and stem cell factor. When very low marrow volumes were injected into lethally irradiated recipient mice, long-term reconstitution with 100% donor cells was seen in all mice injected with HaMDR1- or HaMID-transduced cells. By contrast, engraftment with HaDHFR- or mock-transduced cells ranged from partial to undetectable despite injection of significantly larger marrow volumes. In addition, mice transplanted with expanded HaMDR1- or HaMID-transduced stem cells developed a myeloproliferative disorder that was characterized by an increase in abnormal peripheral blood leukocytes. These results show that MDR1-transduced stem cells can be expanded in vitro with hematopoietic cytokines, but indicate that an increased stem cell division frequency can lead to stem cell damage.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Células de la Médula Ósea/citología , Trasplante de Médula Ósea , Células Madre Hematopoyéticas/citología , Células Madre Hematopoyéticas/fisiología , Retroviridae , Transfección/métodos , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/biosíntesis , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/sangre , Animales , Animales Recién Nacidos , Diferenciación Celular , División Celular , Células Cultivadas , Humanos , Leucocitos/citología , Leucocitos/fisiología , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos , Modelos BiológicosRESUMEN
Human severe combined immunodeficiency (SCID) can be caused by defects in Janus kinase 3 (JAK3)-dependent cytokine signaling pathways. As a result, patients are at high risk of life-threatening infection. A JAK3 -/- SCID mouse model for the human disease has been used to test whether transplant with retrovirally transduced bone marrow (BM) cells (JAK3 BMT) could restore immunity to an influenza A virus. The immune responses also were compared directly with those for mice transplanted with wild-type BM (+/+ BMT). After infection, approximately 90% of the JAK3 BMT or +/+ BMT mice survived, whereas all of the JAK3 -/- mice died within 29 days. Normal levels of influenza-specific IgG were present in plasma from JAK3 BMT mice at 14 days after respiratory challenge, indicating restoration of B cell function. Influenza-specific CD4(+) and CD8(+) T cells were detected in the spleen and lymph nodes, and virus-specific CD8(+) effectors localized to the lungs of the JAK3 BMT mice. The kinetics of the specific host response correlated with complete clearance of the virus within 2 weeks of the initial exposure. By contrast, the JAK3 -/- mice did not show any evidence of viral immunity and were unable to control this viral pneumonia. Retroviral-mediated JAK3 gene transfer thus restores diverse aspects of cellular and humoral immunity and has obvious potential for human autologous BMT.
Asunto(s)
Terapia Genética/métodos , Virus de la Influenza A/inmunología , Proteínas Tirosina Quinasas/genética , Inmunodeficiencia Combinada Grave/terapia , Animales , Anticuerpos Antivirales/sangre , Trasplante de Médula Ósea , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD8-positivos/inmunología , Modelos Animales de Enfermedad , Inmunidad Celular , Memoria Inmunológica , Janus Quinasa 3 , Ratones , Ratones Mutantes , Inmunodeficiencia Combinada Grave/inmunología , Transformación GenéticaRESUMEN
One of the main impediments to effective gene therapy of blood disorders is the resistance of human hematopoietic stem cells to stable genetic modification. We show here that a small minority of retrovirally transduced stem cells can be selectively enriched in vivo, which might be a way to circumvent this obstacle. We constructed two retroviral vectors containing an antifolate-resistant dihydrofolate reductase cDNA transcriptionally linked to a reporter gene. Mice were transplanted with transduced bone marrow cells and then treated with an antifolate-based regimen that kills unmodified stem cells. Drug treatment significantly increased the percentage of vector-expressing peripheral blood erythrocytes, platelets, granulocytes, and T and B lymphocytes. Secondary transplant experiments demonstrated that selection occurred at the level of hematopoietic stem cells. This system for in vivo stem-cell selection provides a means to increase the number of genetically modified cells after transplant, and may circumvent an substantial obstacle to successful gene therapy for human blood diseases.
Asunto(s)
Vectores Genéticos , Trasplante de Células Madre Hematopoyéticas , Retroviridae/genética , Selección Genética , Tetrahidrofolato Deshidrogenasa/genética , Animales , Células Sanguíneas/enzimología , Resistencia a Medicamentos , Femenino , Antagonistas del Ácido Fólico/farmacología , Genes Reporteros , Terapia Genética/métodos , Ratones , Ratones Endogámicos C57BL , Tioinosina/análogos & derivados , Tioinosina/farmacología , Tionucleótidos/farmacología , Transformación Genética , Trimetrexato/farmacologíaAsunto(s)
Técnicas de Transferencia de Gen , Células Madre Hematopoyéticas , Proteínas Luminiscentes , Animales , Biomarcadores , Separación Celular , Terapia Genética/métodos , Proteínas Fluorescentes Verdes , Trasplante de Células Madre Hematopoyéticas , Células Madre Hematopoyéticas/citología , Humanos , Macaca mulatta , Proteínas de la MembranaRESUMEN
Attempts to expand repopulating hematopoietic cells ex vivo have yielded only modest amplification in stem cell numbers. We now report that expression of an exogenous human multi-drug resistance 1 (MDR1) gene enables dramatic ex vivo stem cell expansion in the presence of early acting hematopoietic cytokines. Bone marrow cells were transduced with retroviral vectors expressing either the MDR1 gene or a variant of human dihydrofolate reductase (DHFR), and then expanded for 12 days in the presence of interleukin-3 (IL-3), IL-6, and stem cell factor. When these cells were injected into nonirradiated mice, high levels of long-term engraftment were only seen with MDR1-transduced grafts. To verify that expansion of MDR1-transduced repopulating cells had occurred, competitive repopulation assays were performed using MDR1 expanded grafts. These experiments showed progressive expansion of MDR1-transduced repopulating cells over the expansion period, with a 13-fold overall increase in stem cells after 12 days. In all of the experiments, mice transplanted with expanded MDR1-transduced stem cells developed a myeloproliferative disorder characterized by high peripheral white blood cell counts and splenomegaly. These results show that MDR1-transduced stem cells can be expanded in vitro using hematopoietic cytokines without any drug selection, but enforced stem cell self-renewal divisions can have adverse consequences.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/fisiología , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Trastornos Mieloproliferativos/etiología , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Animales , División Celular , Células Cultivadas/efectos de los fármacos , Células Cultivadas/trasplante , Genes MDR , Vectores Genéticos , Supervivencia de Injerto , Virus del Sarcoma Murino de Harvey/genética , Hematopoyesis/efectos de los fármacos , Humanos , Interleucina-3/farmacología , Interleucina-6/farmacología , Ratones , Ratones Endogámicos C57BL , Trastornos Mieloproliferativos/genética , Trastornos Mieloproliferativos/patología , Factor de Células Madre/farmacología , TransfecciónRESUMEN
Expression of certain variants of dihydrofolate reductase (DHFR) in mammalian cells protects them from methotrexate. Retroviral transfer of the gene for such a variant DHFR into hematopoietic cells might permit selection of modified cells in vivo by antifolate administration or alleviate antifolate-induced myelosuppression in patients receiving antifolate therapy. We examined protection of cells of the human lymphoblastoid line, CCRF-CEM, transduced with variants of mouse DHFR. In transduced cells selected with G418 but not with antifolate, the variant that had arginine substituted for leucine 22 did not protect against either methotrexate or trimetrexate; however, four other variants did offer protection, with the best having leucine 22 changed to tyrosine. Polyclonal cultures transduced with the different variants express DHFR at about the same level, but clones within each polyclonal population differ in DHFR expression levels and in resistance. These differences in expression were shown to reflect different integration sites for proviral DNA. Exposure to trimetrexate selects highly resistant clones, with high expression due to both high copy number and integration sites that are favorable for expression. Differences in the resistance of cultures expressing different variants at the same level are due to differences in the catalytic activity of the expressed DHFR, its affinity for antifolates, and its stability.
Asunto(s)
Antagonistas del Ácido Fólico/farmacología , Técnicas de Transferencia de Gen , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/enzimología , Tetrahidrofolato Deshidrogenasa/genética , Animales , Clonación Molecular , Resistencia a Antineoplásicos , Estabilidad de Enzimas/genética , Escherichia coli/genética , Dosificación de Gen , Regulación Neoplásica de la Expresión Génica , Humanos , Metotrexato/farmacología , Ratones , Mutación , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Retroviridae/genética , Tetrahidrofolato Deshidrogenasa/metabolismo , Trimetrexato/farmacología , Células Tumorales CultivadasRESUMEN
Mammalian cells cultured in the presence of the chemotherapeutic agent, methotrexate, develop resistance to this drug. Sometimes this is due to mutations in the gene for dihydrofolate reductase, the primary target of methotrexate. However, it has not been possible to link such polymorphism to resistance of neoplastic disease to therapy with methotrexate. Nevertheless, interest in this possibility lead to the introduction of many mutations into the cDNA for human DHFR by mutagenesis. Most of the corresponding enzyme variants have been expressed in Escherichia coli and characterized. Many mutations in codons for hydrophobic residues at the active site greatly decrease inhibition by methotrexate, and by the related substrate analogue, trimetrexate, while allowing the retention of considerable catalytic efficiency. Introduction of some of these mutants into mammalian cells by retroviral transfer provides substantial protection from toxic effects of the inhibitors, and has promise for the myeloprotection of patients receiving therapy with methotrexate or trimetrexate. Another potential use is in therapy for inherited disorders of hematopoiesis, where genetic modification of enough cells is a perennial problem. After transplantation of bone marrow that has been transduced with a bicistronic vector encoding both the mutant DHFR and a therapeutic gene, subsequent administration of methotrexate or trimetrexate should permit selection and enrichment of genetically modified hematopoietic cells.